Drug Profile
GSK 6097608
Alternative Names: GSK-6097608; GSK’608; GSK’608 CD96Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer 23andMe; GSK
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD96 antigen inhibitors; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Squamous cell cancer
- Phase I Solid tumours
Most Recent Events
- 14 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Argentina (IV) (NCT06062420) (EudraCT2023-503428-24-00)
- 14 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Brazil (IV) (NCT06062420) (EudraCT2023-503428-24-00)
- 14 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (IV) (NCT06062420) (EudraCT2023-503428-24-00)